Precision Spinal Cord Stimulator System Clinician Manual Rev A

Precision™ Spinal Cord Stimulator System Clinician Manual Guarantees Boston Scientific Corporation reserves the right to modify, without prior notice, information relating to its products in order to improve their reliability or operating capacity. Drawings are for illustration purposes only.

Trademarks All trademarks are the property of their respective holders. Additional Information For device-specific information not included in this manual, see the appropriate Directions for Use as listed in the Reference Guide.

Clinician Manual 91083273-01 Rev A

ii of iv



Table of Contents Manual Overview ... 1 Device and Product Description ... 2 Implantable Pulse Generator ...2 Leads ...2 Lead Extension ...2 Lead Splitter...3

Indications for Use ... 4

Precision System Clinical Summary ...4

Contraindications ... 8 Safety Information... 9 Instructions for the Patient...9 Warnings ...9 Precautions ...9 Adverse Effects ... 11 Instructions for the Physician ... 11

Package Contents ... 13

IPG Kit ...13 Percutaneous Permanent Lead Kit ...13 Percutaneous Trial Lead Kit...13 Lead Extension Kit ...13 2x4 Splitter Kit...14 Surgical Paddle Lead Kit ...14 Infinion™ 16 Lead Kit...14 Infinion 16 Trial Lead Kit...14 Infinion CX Lead Kit...15 Infinion CX Lead Trial Lead Kit...15 Splitter 2x8 Kit...15 Infinion™ 16 Trial Configuration Kit...15 Infinion™ 16 Configuration Kit...15

Sterilization, Handling, and Storage ... 16

Sterilization ...16 IPG Handling and Storage ...16 Lead, Lead Extension, and Splitter Handling and Storage...17

Pre-Op Instructions ... 18 Percutaneous Lead Placement in the Epidural Space ... 19 Infinion CX Lead Placement in the Epidural Space with Entrada™ Needle...20 Lead Connection to Splitter...25

Surgical Paddle Lead Placement in the Epidural Space ... 28 Connecting the OR Cable Assembly ... 29 Intraoperative Stimulation Testing ... 30 Securing the Trial Lead ... 31 Securing the Infinion CX Trial Lead ... 32 Permanent Lead Anchoring and Tunneling... 33

Anchoring the Lead ...34 Tunneling the Lead or Lead Extension ...35 Clinician Manual 91083273-01 Rev A iii of iv

Precision™ Spinal Cord Stimulator System Clinician Manual Connecting the Lead Extension ...37

Connecting to the Trial Stimulator ... 39 Removal of Trial Leads, Extensions, and Splitters... 40

Option A: Percutaneous Lead Removal after Temporary Trial ...40 Option B: Lead Extension Removal after Permanent Trial ...40 Option C: Splitter Removal after Trial...40

IPG Implantation ... 41 Connecting to the IPG ... 42

For Percutaneous Lead - Dual Lead Connection ...42 For Infinion™ 16 Lead Connection...42 For Infinion CX Lead Connection...42 For Percutaneous Lead - Single Lead Connection ...42 For Surgical Paddle Lead Connection ...42 Programming with the Infinion 16 Lead and Infinion CX Lead...44

IPG Explant or Replacement ... 45 Rechargeable Stimulator System ... 46

IPG Battery Status ...46 Charging Steps ...47 Patient Remote Control...48 Device Linking ...53 Searching ...53 Clinician Options...54

Specifications and Technical Data ... 59

Materials ...59 Max Current Amp. per Electrode vs. Impedance ...60

Registration Information... 63

Registering the Stimulator and Leads ...63

Technical Service ... 64 Limited Warranty - IPG ... 65 Limited Warranty - Leads ... 66 Limited Warranty - Externals... 67

Clinician Manual 91083273-01 Rev A

iv of iv

Manual Overview

Manual Overview This manual provides basic information for the trial, implantation, and operation of the Boston Scientific Precision Spinal Cord Stimulator (SCS) system. General surgical guidelines are presented in this manual for temporary and permanent implantation of Boston Scientific percutaneous leads, lead extensions, splitters, surgical paddle leads, and implantable pulse generator (IPG). These products are designed to aid in the management of chronic intractable pain. This manual also provides an overview of accessories for programming and charging the IPG, clinical and surgical considerations, storage and handling requirements, and relevant precautions concerning an implanted neurostimulator. Additional information on system components and operation can be found in the Bionic Navigator™ Software Guide.

Clinician Manual 91083273-01 Rev A 1 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual

Device and Product Description The Precision system consists of an implantable pulse generator, temporary and permanent percutaneous leads, surgical paddle leads, and lead extensions, each packaged as a separate kit. Single use accessories and disposable tools are also included in these kits. Features of the Precision SCS System include: • • • • • • • •

Stimulation electrode field navigation Sixteen independent current-controlled electrodes Four programmable stimulation areas per program; four possible programs Long-life operation High-range parameter capability Small size Two-foot programming range This product contains no detectable latex

Implantable Pulse Generator The Precision Implantable Pulse Generator (IPG) system is intended to treat chronic pain by electrically stimulating the spinal cord. The multi-channel, multi-electrode device capability provides flexibility in conjunction with ease of programming. A rechargeable battery increases IPG longevity and output capability while reducing size and device replacement surgeries. The IPG is controlled by a handheld Remote Control, and can be engaged by a clinician computer using proprietary Bionic Navigator software. Periodically, the IPG battery requires replenishing with an RF charging device provided separately in the Patient Charging Kit.

Leads The percutaneous and surgical paddle leads function as a component of the Precision SCS system by delivering electrical stimulation to the nerve structures in the dorsal aspect of the spinal cord, resulting in an inhibition of pain sensation.

Surgical Paddle Lead The 2x8 Surgical Paddle Lead is available in lengths of 50 cm and 70 cm. The distal (paddle) end of the lead has two columns of eight evenly spaced planar electrodes. Each electrode is 3x2 mm2 in area. On the proximal side, this lead employs 2 lead tails. The end of each tail has eight evenly spaced contacts, identical to the percutaneous leads. The right tail of the Paddle Lead is laser-etched to allow for ease of right and left identification. Each tail can be inserted into an IPG or into a lead extension.

Percutaneous Leads The eight-contact percutaneous leads are available in lengths of 30 cm, 50 cm, and 70 cm. Each lead has eight electrode contacts located near the distal end. Each contact is 3 mm in length and is spaced 1, 4, or 6 mm from the adjacent contact. The 16 contact percutaneous lead (Infinion™ 16 Lead and Infinion CX Lead) is available in lengths of 50 cm and 70 cm. Each lead has 16 contacts located near the distal end. Each contact is 3 mm in length and is spaced 1 mm from the adjacent contact. The Infinion 16 lead must be inserted into a Splitter 2x8 which then connects to a Precision IPG’s 8 contact ports or 8 contact OR Cables.

Lead Extension Lead Extensions are designed to connect the percutaneous and paddle leads to the Precision IPG for spinal cord stimulation. The extension may be added to a lead to externalize the lead for a trial procedure or to extend the lead when a permanent IPG is implanted. Clinician Manual 91083273-01 Rev A

2 of 69

Device and Product Description Lead extensions are available in lengths of 25 cm, 35 cm, and 55 cm. Each extension has eight electrode contacts located near the distal end. Each contact is 3 mm in length and is spaced 1 mm from the adjacent contact. The extension can be connected to either the Trial Stimulator (via an OR Cable Assembly included in the Leads Kit) or directly to the Precision IPG.

Lead Splitter The 2x4 Splitters are designed to connect multiple percutaneous leads to the Precision IPG. The Linear leads may be inserted into a splitter for a maximum of four Linear leads per IPG. Four of the eight contacts of each Linear lead will be activated. Two configurations of 2x4 splitters are available: Distal 4 (D4) and Wide 4 (W4). The two versions offer different contact configurations. The Lead Splitter 2x8 is required to connect the Infinion 16 contact lead to the IPG. Only one Infinion 16 lead through one Splitter 2x8 can be connected to a Precision IPG.

Clinician Manual 91083273-01 Rev A 3 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual

Indications for Use The Boston Scientific PRECISION Spinal Cord Stimulator System (PRECISION System) is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.

Precision System Clinical Summary Determination of the safety and effectiveness of the PRECISION System was based on available published clinical studies for similar implanted spinal cord stimulation systems. The PRECISION System is similar to the SCS systems reported in published literature in intended use, target patient population, technology, device design, and output characteristics. Therefore, the clinical data from the published literature described below represents evidence supporting the safety and effectiveness of the PRECISION System for the treatment chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain.

Efficacy Evaluation Three (3) clinical literature studies were used to support the effectiveness of the PRECISION System (Ohnmeiss et al. 1996, Villavicencio et al. 2000, Hassenbusch SJ et al. 1995). The studies included a total of 116 patients that were implanted with an SCS system. A total of approximately 3166 device months of experience was depicted from the retrospective clinical evaluation. All three studies examined the effectiveness of SCS on patients with chronic pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome or intractable low back and leg pain. In all studies, a totally implantable spinal cord stimulator was used in association with a percutaneous and/or surgical lead. These studies provide the same diagnostic or therapeutic intervention for the same disease/ conditions and patient population as the PRECISION System. The prospective study by Ohnmeiss et al. 1996, examined the long-term effectiveness of SCS in patients with intractable leg pain. Forty patients were implanted with SCS systems and evaluated at 6 weeks, 12 months, and 24 months follow-up. Outcome measures included the VAS, pain drawings, medication use, SIP (Sickness Impact Profile), isometric lower extremity testing, and patient questionnaires. An intent-to-treat analysis was performed. After patients had SCS for 24 months, leg pain, pain when walking, standing pain, pain’s effect on overall lifestyle, and the total analog scale scores were significantly improved from baseline. In this study, 25% of the implanted patients had greater than 50% improvement in pain rating. In addition, 3 patients from this study had their stimulators repositioned due to pain at the original location. Three patients had reoperations to adjust lead position; 1 patient required 2 reoperations, 1 patient had the device removed due to infection and later to have a new device implanted. A diabetic patient had skin problems which required device removal; a new device was later implanted. Two patients had the device removed due to unsatisfactory pain relief. The prospective study performed by Villavicencio et al. 2000 included 41 patients with pain of various etiologies. The majority of the patients, 24 (59%), had Failed Back Surgery Syndrome (FBSS), 7 (17%) had Complex Regional Pain Syndrome (CRPS I and II), 4 (10%) had neuropathic pain syndrome, and 6 (15%) were diagnosed as stroke or other. Patients underwent an initial trial period for SCS with temporary leads. If the trial resulted in greater than 50% reduction in the patient’s pain, as measured by the VAS, the patient was implanted with a SCS system. In this study, 27/41 patients, 66%, had permanent implants. All patients were examined after 6 weeks. Pain measurements were assessed at 3-6 month intervals for the first year and annually thereafter. The median long-term follow-up was 34 months. A total of 24/27 (89%), reported greater than 50% reduction in pain. Since the majority of the patients were treated for FBSS, this article supports the use of SCS for the treatment of FBSS. Clinician Manual 91083273-01 Rev A

4 of 69

Indications for Use In this study, one patient required a revision because of electrode fracture. One patient required removal of the system due to local infection. One patient required replacement of the IPG due to mechanical failure. Overall, 16 of 27 (59%) patients required a total of 36 repositioning procedures. A retrospective analysis performed by Hassenbusch SJ et al. 1995 included patients with chronic lower body pain, predominately neuropathic pain and pain either midline lower back and/or unilateral or bilateral leg pain treated over a 5 year period. The study was a comparison of SCS to spinal infusion of opioids. For patients with radicular pain involving one leg with or without unilateral buttock pain, a trial of SCS was recommended first. For patients with midline back pain and /or bilateral leg pain, a trial of long-term spinal infusion was recommended first. If the patients failed screening with either of these modalities, the other was then tested. If the treatment reduced the pain by 50%, the systems were internalized. A retrospective analysis of patients with unilateral leg and/or buttock pain treated initially with SCS and bilateral leg or mainly low back pain treated initially with spinal infusions of opioids was then done. In this study, 42 patients were screened; 26 (62%) patients received spinal stimulation; 16 (38%) received opioids via a spinal infusion pump. Five patients did not receive adequate pain relief with SCS; 3 (7%) of these patients underwent trial spinal infusions and had effective pain relief. There were 4 (10%) patients who underwent a trial of spinal infusion of opioid but did not receive adequate pain relief; these patients were not tested with SCS. Pain severity was rated using a verbal digital pain scale: “On a scale of 0 to 10 where 0 is no pain and 10 is the worst pain you could ever imagine, what is your pain now?” 16/26 patients (62%) had greater than 50% pain relief with SCS. In this study, 2/16 (13%) had greater than 50% pain relief with opioids. Mean follow-up was 2.1 ± 0.3 years. This analysis supports the use of SCS for intractable low back and leg pain. In this study, 7 (17%) patients suffered complications after implantation of the device; 5 (12%) patients required repositioning of catheter type electrodes and 2 patients required revision of the stimulator generator.

Safety Evaluation Eleven studies were identified based on the detailed inclusion/exclusion criteria to demonstrate the safety of the PRECISION System. The studies included a total of 1056 patients that were trialed with SCS systems and 880 patients that received implants. The table below depicts the number of patients, the number of events, and the percentage of occurrences of each event compared to the total number of patients. It should be noted that citations cover both IPG and RF systems. The clinical experience reported in the literature on RF systems is relevant to determining the safety of totally implantable IPG systems.

Clinician Manual 91083273-01 Rev A 5 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual Table 1: Summary of Risks Identified in the Retrospective Clinical Studies Risks

# Patients With Adverse Event

Intent-to-Treat Basis N = 1056

Implanted Patient Basis N = 880

Lead Migration

175

16.6%

19.9%

Infection

39

3.7%

4.4%

Epidural Hemorrhage

0

0%

0%

Seroma

0

0%

0%

Hematoma

1

0.1%

0.1%

Paralysis

0

0%

0%

CSF Leak

5

0.5%

0.6%

Over/Under Stimulation, Ineffective Pain Control

46

4.4%

5.2%

Intermittent Stimulation

0

0%

0%

Pain Over Implant

16

1.5%

1.8%

Allergic Reaction

6

0.6%

0.7%

Skin Erosion

0

0%

0%

Lead Breakage

35

3.3%

4.0%

Hardware Malfunction

22

2.1%

2.5%

Loose Connection

0

0%

0%

Battery Failure

2

0.2%

0.2%

Other

45

4.3%

5.1%

Clinical Experience-Safety Clinical data has been collected during a clinical study of the PRECISION System. As of January 15, 2004, 35 subjects were enrolled in the study at multiple sites and 26 subjects had a successful trial stimulation period and were implanted with the PRECISION System. The follow-up period for the 26 implanted patients ranged from 2 weeks to 6 months. The following major adverse events were reported. Table 2: Clinical Experience Safety Type

Number of Patients

Resolution

Lead Migration

1

Lead repositioning and subsequent replacement

Output malfunction

1

Device replaced

Infection

1

Infection treated

Pain

1

Lead explanted

Other minor adverse events reported by at least one patient included: receiver malfunction, skin irritation, unpleasant stimulation, CSF leak, infection at implant site, lead migration, and OR cable malfunction. Two of the subjects reported multiple events.

Clinician Manual 91083273-01 Rev A

6 of 69

Indications for Use References Burchiel, K.J., V.C. Anderson, F.D. Brown, R.G. Fessler, W.A. Friedman, S. Pelofsky, R.L. Weiner, J. Oakley,and D. Shatin. “Prospective, Multicenter Study of Spinal Cord Stimulation for Relief of Chronic Back and Extremity Pain.” Spine, 21:2786-2793, 1996. Hassenbusch, S.J., M. Stanton-Hicks, E.C. Covington. “Spinal cord stimulation verses spinal infusion for low back and leg pain”. Acta Neurochirgica, 64:109-115, 1995. Kemler, M.A., G.A.M. Barendse, M. Van Kleef, H.C.W. De Vet, C.P.M. Rijks, C.A. Furnee and F.A.J.M. Van den Wilderberg. “Spinal Cord Stimulation in Patients with Chronic Reflex Sympathetic Dystrophy.” New England J of Medicine, 343: 618-24, 2000. Kim S. H., R.R. Tasker, and M.Y. Oh. “Spinal Cord Stimulation for Nonspecific Limb Pain versus Neuropathic Pain and Spontaneous versus Evoked Pain.” Neurosurgery, 48(5): 1056-1064, 2001. Kumar, K., C. Toth, R. Nath, and P. Lang. “Epidural Spinal Cord Stimulation for Treatment of Chronic PainSome Predictors of Success. A 15 year experience.” Surg Neurol, 50: 110-120, 1998. Lang, P. “The Treatment of Chronic Pain by Epidural Spinal Cord Stimulation.” AXON, 18(4): 71-73, 1997. Ohnmeiss, D., R. Rashbaum, M. Bogdanffy. Prospective Outcome Evaluation of Spinal Cord Stimulation in Patients With Intractable Leg Pain. Spine, 21:1344­1351, 1996. Rainov, N.G., V. Heidecke, and W. Burkert. “Short Test-Period Spinal Cord Stimulation for Failed Back Surgery Syndrome.” Minim Invasive Neurosurg, 39(2):41-44, 1996. Segal, R., B. Stacey, T. Rudy, S. Basser, J. Markham. “Spinal Cord Stimulation Revisited.” Neurological Research, 20:391-396, 1998. Spieglemann, R. and W.A. Friedman. “Spinal Cord Stimulation: A Contemporary Series.” Neurosurg 28:65-71, 1991. Villavicencio, A.T., J.C. Leveque, L. Rubin, K. Bulsara, and J.P. Gorecki. “Laminectomy versus percutaneous electrode placement for spinal cord stimulation.” Neurosurgery, 46:399-406, 2000.

Clinician Manual 91083273-01 Rev A 7 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual

Contraindications Patients contraindicated for permanent SCS therapy are those who: • • • •

are unable to operate the SCS system have failed trial stimulation by failing to receive effective pain relief are poor surgical risks are pregnant

Clinician Manual 91083273-01 Rev A

8 of 69

Safety Information

Safety Information Instructions for the Patient Warnings Heat Due to Charging. Do not charge while sleeping. This may result in a burn.While charging, the Charger may become warm. It should be handled with care. Failure to use the Charger with either the Charging Belt or an adhesive patch, as shown, may result in a burn. If you experience pain or discomfort, cease charging and contact Boston Scientific. Magnetic Resonance Imaging (MRI). Patients implanted with the Precision SCS system should not be subjected to MRI. MRI exposure may result in dislodgement of implanted components, heating of the neurostimulator, damage to the device electronics and/or voltage induction through the leads and Stimulator causing an uncomfortable or “jolting” sensation. Pediatric Use. The safety and effectiveness of spinal cord stimulation has not been established for pediatric use. Diathermy. Shortwave, microwave and/or therapeutic ultrasound diathermy should not be used on SCS patients. The energy generated by diathermy can be transferred through the Stimulator system, causing tissue damage at the lead site and resulting in severe injury or death. The IPG, whether it is turned on or off, may be damaged. Implanted Stimulation Devices. Spinal cord stimulators may interfere with the operation of implanted sensing stimulators such as pacemakers or cardioverter defibrillators. The effects of implanted stimulation devices on neurostimulators is unknown. Stimulator Damage. Burns may result if the pulse generator case is ruptured or pierced and patient tissue is exposed to battery chemicals. Do not implant the device if the case is damaged. Postural Changes. Patients should be advised that changes in posture or abrupt movements may cause decreases, or uncomfortable or painful increases in the perceived stimulation level. Patients should be advised to turn down the amplitude or turn off the IPG before making posture changes. If unpleasant sensations occur, the IPG should be turned off immediately. Electromagnetic Interference. Strong electromagnetic fields can potentially turn the Stimulator off, or cause uncomfortable or jolting stimulation. Patients should be counseled to avoid or exercise care around: •

• • •

Theft detectors or security screeners such as those used at entrances/exits of department stores, libraries, and other public establishments, and/or airport security screening devices. It is recommended thatpatients request assistance to bypass the device. If they must proceed through the device, the patient should turn off the Stimulator and proceed with caution, ensuring to move through the center of the screener as quickly as possible. Power lines or power generators Electric steel furnaces and arc welders Large, magnetized stereo speakers

Precautions Physician training is required. Medical Devices/Therapies. The following medical therapies or procedures may turn stimulation off or may cause permanent damage to the Stimulator, particularly if used in close proximity to the device: • • •

lithotripsy electrocautery: Do not use monopolar cautery. See “Instructions for the Physician” on page 11 external defibrillation Clinician Manual 91083273-01 Rev A 9 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual • • •

radiation therapy ultrasonic scanning high-output ultrasound

If any of the above is required by medical necessity, refer to “Instructions for the Physician” on page 11 . Ultimately, however, the device may require explantation as a result of damage to the device. Automobiles and Other Equipment. Patients should not operate automobiles, other motorized vehicles, or potentially dangerous machinery/ equipment with therapeutic stimulation switched on. Stimulation must be turned off first. Sudden stimulation changes, if they occur, may distract patients from attentive operation of the vehicle or equipment. Post Operative. During the two weeks following surgery, it is important to use extreme care so that appropriate healing will secure the implanted components and close the surgical incisions: • • •

Do not lift objects of more than five pounds. Do not engage in rigorous physical activity such as twisting, bending, or climbing. If new leads were implanted, do not raise your arms above your head.

Temporarily, there may be some pain in the area of the implant as the incisions heal. If discomfort continues beyond two weeks, contact your physician. If you notice excessive redness around the wound areas during this time, contact your physician to check for infection and administer proper treatment. In rare cases, adverse tissue reaction to implanted materials can occur during this period. Be sure to consult your physician before making lifestyle changes due to decreases in pain. Stimulator Location. Never attempt to change the orientation or “flip” the Stimulator. Do not “finger” or play with the Stimulator. If the Stimulator flips over in your body, it cannot be charged. If you know that the device has turned, or if stimulation cannot be turned on after charging, contact your physician to arrange an evaluation of the system. In some cases, the skin over your Stimulator may become very thin over time. If this occurs, contact your physician. Lead Location. In some instances a lead can move from its original location, and stimulation at the intended pain site can be lost. If this occurs, consult your physician who may able to restore stimulation by reprogramming the Stimulator in the clinic or repositioning the lead during another operation. Device Failure. Stimulators can fail at any time due to random component failure, loss of battery functionality, or lead breakage. If the device stops working even after complete charging (up to four hours), turn off the Stimulator and contact your physician so that the system can be evaluated. Storage, Handling and Transport. Do not expose the Remote Control or Charging System components to excessively hot or cold conditions. Do not leave the devices in your car or outdoors for extended periods of time. The sensitive electronics can be damaged by temperature extremes, particularly high heat. For proper operation, do not use the Charger if the ambient temperature is above 35 °C (95 °F). If the Remote Control or the Charging System is to be stored for a period of time without batteries, the storage temperature should not exceed -20 to 60 °C (-4 to 140 °F). Handle the system components and accessories with care. Do not drop them or submerge them in water. Although reliability testing has been performed to ensure quality manufacturing and performance, dropping the devices on hard surfaces or in water, or other rough handling, can permanently damage the components. (See “Limited Warranty - IPG” on page 65.) Component Disposal. Do not dispose of the Remote Control or Charger in fire. The battery in these devices can explode in fire. Dispose of used batteries in accordance with local regulations. The IPG should be explanted in the case of cremation, and returned to Boston Scientific. External devices to be disposed of per local regulatory requirements. Please contact your healthcare professional. Clinician Manual 91083273-01 Rev A

10 of 69

Safety Information Remote Control, Charging System Cleaning. The components can be cleaned using alcohol or a mild detergent applied with a cloth or tissue. Residue from soapy detergents should be removed with a damp cloth. Do not use abrasive cleansers for cleaning. Cell Phones. While we do not anticipate any interference with cell phones, the full effects of interaction with cell phones are unknown at this time. If there is a concern or a problem is encountered, the physician should be contacted.

Adverse Effects Potential risks are involved with any surgery. The possible risks of implanting a pulse generator as part of a system to deliver spinal cord stimulation include: • •

• • • • • • • • • • • • •

Lead migration, resulting in undesirable changes in stimulation and subsequent reduction in pain relief. System failure, which can occur at any time due to random failure(s) of the components or the battery. These events, which may include device failure, lead breakage, hardware malfunctions, loose connections, electrical shorts or open circuits and lead insulation breaches, can result in ineffective pain control. Tissue reaction to implanted materials can occur. In some cases, the formation of reactive tissue around the lead in the epidural space can result in delayed onset of spinal cord compression and neurological/sensory deficit, including paralysis. Time to onset is variable, possibly ranging from weeks to years after implant. Skin erosion at the IPG site can occur over time. Possible surgical procedural risks are: temporary pain at the implant site, infection, cerebrospinal fluid (CSF) leakage and, although rare, epidural hemorrhage, seroma, hematoma and paralysis. External sources of electromagnetic interference may cause the device to malfunction and affect stimulation. Exposure to MRI can result in heating of tissue, image artifacts, induced voltages in the neurostimulator and/or leads, lead dislodgement. Undesirable stimulation may occur over time due to cellular changes in tissue around the electrodes, changes in electrode position, loose electrical connections and/or lead failure. The patient may experience painful electrical stimulation of the chest wall as a result of stimulation of certain nerve roots several weeks after surgery. Over time, the Stimulator may move from its original position. Weakness, clumsiness, numbness or pain below the level of implantation. Persistent pain at the IPG or lead site.

In any event, instruct the patient to contact their physician to inform him/her.

Instructions for the Physician Implanted Stimulation Devices. If such implanted devices are indicated for the patient, careful screening is required to determine if safe results can be achieved before permanently implementing concurrent electrical therapies. Postural Changes. Depending on the activity level of the patient, postural changes may affect stimulation intensity. Instruct patients to keep the Remote Control on hand at all times, and ensure that they understand how to adjust stimulation levels. Medical Devices/Therapies. If the patient is required to undergo lithotripsy, electrocautery, external defibrillation, radiation therapy, ultrasonic scanning, or high-output ultrasound: •

Turn off stimulation at least five minutes before the procedure or application. Clinician Manual 91083273-01 Rev A 11 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual • • • • •

All equipment, including ground plates and paddles, must be used as far away from the IPG as possible. Bipolar electrocautery is recommended. Do not use monopolar electrocautery. Every effort should be taken to keep fields, including current, radiation, or high-output ultrasonic beams, away from the IPG. Equipment should be set to the lowest energy setting clinically indicated. Instruct patients to confirm IPG functionality following treatment by turning on the IPG and gradually increasing stimulation to the desired level.

Clinician Manual 91083273-01 Rev A

12 of 69

Package Contents

Package Contents IPG Kit (1) (1) (1) (1) (2) (1) (1)

Precision Implantable Pulse Generator Hex Wrench Tunneling Tool Assembly IPG Pocket Template Port Plugs Device Registration Form/Temporary Patient Identification Card Manual

Percutaneous Permanent Lead Kit (1) (1) (4) (1) (1) (1) (1) (2) (1) (1)

Percutaneous Lead with pre-loaded Curved Stylet Stylet Ring with a Curved and a Straight Stylet Suture Sleeves Insertion Needle with Stylet Lead Blank Steering Cap OR Cable Assembly Lead Position Labels-left and right (non-sterile) Device Registration Form/Temporary Patient Identification Card Manual

Percutaneous Trial Lead Kit (1) (1) (1) (1) (1) (2) (1) (1)

Percutaneous Lead with pre-loaded Curved Stylet Suture Sleeve Insertion Needle with Stylet Steering Cap OR Cable Assembly Lead Position Labels-left and right (non-sterile) Manual Device Registration Form/Temporary Patient Identification Card

Lead Extension Kit (1) (1) (1) (1) (1)

Lead Extension Hex Wrench Tunneling Tool Assembly Device Registration Form/Temporary Patient Identification Card Manual

Clinician Manual 91083273-01 Rev A 13 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual

2x4 Splitter Kit (1) (1) (1) (1)

Splitter Hex wrench Manual and Insert Device Registration Form/Temporary Patient Identification Card

Surgical Paddle Lead Kit (1) (4) (2) (2) (1) (1)

Paddle Lead Suture Sleeves OR Cable Assemblies Lead Position Labels-left and right (non-sterile) Device Registration Form/Temporary Patient Identification Card Manual

Infinion 16 Lead Kit (1) (1) (1) (4) (1) (1) (2) (1) (1) (1)

16 Contact Lead with pre-loaded Curved Stylet Stylet Ring with a Curved and a Straight Stylet Straight Stylet Suture Sleeves Insertion Needle Lead blank Lead Position Labels-left and right (non-sterile) Manual Product Registration Form/Temporary Patient Identification Card Steering Cap

Infinion 16 Trial Lead Kit (1) (1) (1) (2)

16 Contact Percutaneous Lead with pre-loaded Curved Stylet Suture Sleeve Insertion Needle Lead Position Labels-left and right (non-sterile)

(1) Manual (1) Product Registration Form/Temporary Patient Identification Card (1) Steering Cap

Clinician Manual 91083273-01 Rev A

14 of 69

Package Contents

Infinion CX Lead Kit (1) 16 Contact Percutaneous Infinion CX Lead with pre-loaded Curved Stylet (2) Suture Sleeves (2) Lead Position Labels-left and right (non-sterile) (1) Manual (1) Product Registration Form/TemporaryPatient Identification Card (1) Steering Cap

Infinion CX Lead Trial Lead Kit (1) 16 Contact Percutaneous Infinion CX Lead with pre-loaded Curved Stylet (2) Suture Sleeves (2) Lead Position Labels-left and right (non-sterile) (1) Manual (1) Product Registration Form/Temporary Patient Identification Card (1) Steering Cap

Splitter 2x8 Kit (1) (1) (1) (1)

Splitter 2x8 Torque Wrench Manual Product Registration Form/Temporary Patient Identification Card

Infinion 16 Trial Configuration Kit (1) Infinion™ 16 Trial Lead Kit (1) 2x8 Splitter Kit

Infinion 16 Configuration Kit (1) Infinion™ 16 Lead Kit (1) 2x8 Splitter Kit

Clinician Manual 91083273-01 Rev A 15 of 69

Precision™ Spinal Cord Stimulator System Clinician Manual

Sterilization, Handling, and Storage Sterilization All Precision system implantable and surgical components are sterilized with ethylene oxide. Inspect the condition of the sterile package before opening the package and using the contents. Do not use the contents if the package is broken or torn, or if contamination is suspected because of a defective sterile package seal. • • • • • •

Do not use any component that shows signs of damage. Do not resterilize the package or the contents. Obtain a sterile package from Boston Scientific. Do not use the product if the labeled “Use By” date has passed. All components are for single use only. Do not reuse. Do not use if package is opened or damaged Do not use if labeling is incomplete or illegible.

WARNING: Contents supplied STERILE using an ethylene oxide (EO) process. Do not use if sterile barrier is damaged. If damage is found, call your Boston Scientific representative. For Single Use Only. Do Not Reuse. Do Not Resterilize. Do not use if package is damaged. For single patient use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness or death. Reuse, reprocessing or resterilization may also create a risk of contamination of the device and/or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient. After use, dispose of product and packaging in accordance with hospital, administrative and/or local government policy.

IPG Handling and Storage • • • •

Handle the IPG and all components with care. Keep sharp instruments away from the components. Do not use the IPG if it has been dropped on a hard surface from a height of more than one foot. Do not incinerate an IPG. Improper disposal of the device could result in an explosion. Devices should be explanted in the case of cremation, and returned to Boston Scientific Neuromodulation. An explant kit is available.

Store the IPG between 0 °C and 45 °C (32 °F and 113 °F). Devices should always be kept in temperature regulated areas within the acceptable temperature range. IPG damage can occur at temperatures outside of this range.

Clinician Manual 91083273-01 Rev A

16 of 69